세계의 희소 바이오마커 검체 수집 및 안정화 시장 보고서(2025년)
Rare Biomarkers Specimen Collection And Stabilization Global Market Report 2025
상품코드 : 1825888
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ₩ 6,448,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ₩ 9,320,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ₩ 12,193,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

희소 바이오마커 검체 수집 및 안정화 시장 규모는 향후 몇 년 동안 강력한 성장이 예상됩니다. 2029년에는 CAGR 9.8%로 512억 2,000만 달러로 성장할 것입니다. 예측 기간의 성장은 액체 생검 적용 확대, 소비자 인식 및 수요 증가, 비침습적 기술 채택 증가, 희귀질환의 바이오마커 탐색에 기인하는 것으로 보입니다. 예측 기간의 주요 동향으로는 보존 기술의 발전, 유전체 및 단백질체학 연구의 성장, POC(Point-of-Care) 검사의 출현, 규제 발전 및 표준화, 데이터 분석 강화, AI의 통합 등이 있습니다.

향후 5년간 9.8%의 성장률 전망은 지난번 전망치보다 0.6% 소폭 하락한 수치입니다. 이 감소는 주로 미국과 다른 국가 간의 관세의 영향에 기인합니다. 관세 부과는 덴마크와 중국에서 수입되는 동결보존 튜브와 안정화 시약에 대한 접근을 제한하고, 희귀질환 연구를 저해하며, 바이오뱅크의 비용을 증가시킬 수 있기 때문에 미국 연구소에 큰 도전이 될 수 있습니다. 또한, 상호 관세와 무역 긴장과 제한의 증가로 인한 세계 경제와 무역에 대한 악영향으로 인해 그 영향은 더욱 광범위하게 나타날 것으로 보입니다.

암 유병률의 증가는 희소 바이오마커 검체 수집 및 안정화 시장의 성장을 촉진할 것으로 예상됩니다. 비정상 세포의 무질서한 증식과 확산을 특징으로 하는 암은 유전적 소인을 악화시키는 환경오염물질과 흡연, 식습관 장애 등의 생활습관 요인으로 인해 유병률이 증가하고 있습니다. 희귀 바이오마커 시료의 수집 및 안정화 방법을 암 유병률 조사에 활용하면 특정 암종을 보다 정확하게 검출하고 모니터링할 수 있어 진단 및 치료 접근법을 강화할 수 있습니다. 예를 들어, 2023년 10월 유럽에 기반을 둔 관리 기관인 유럽위원회의 보고서에 따르면, 2022년 신규 암 환자 수는 274만 명으로 2020년 대비 2.3% 증가할 것으로 예상했습니다. 그 결과, 암 유병률의 증가가 희소 바이오마커 검체 수집 및 안정화 시장의 성장을 견인하고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세, 그리고 코로나와 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별·국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 개요

제31장 기타 주요 기업과 혁신적 기업

제32장 세계의 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병

제34장 최근의 시장 동향

제35장 시장 잠재력이 높은 국가, 부문, 전략

제36장 부록

KSM
영문 목차

영문목차

Rare biomarkers specimen collection and stabilization involves the process of gathering and preserving biological samples that contain rare or low-abundance molecules, which indicate specific biological processes, diseases, or conditions. These biomarkers can include specific proteins, nucleic acids, metabolites, or other substances. The goal of collecting and preserving these rare biomarkers is to allow for accurate and reliable measurement and analysis for diagnostic, prognostic, and therapeutic purposes.

The primary types of rare biomarker specimen collection and stabilization include circulating cell-free DNA (ccFDNA), circulating tumor cells (CTCs), exosomes, and extracellular vesicles. Circulating cell-free DNA (ccFDNA) consists of DNA fragments freely circulating in the bloodstream, originating from both healthy and diseased cells. These fragments carry genetic information and can be analyzed for various diagnostic purposes, such as cancer detection or monitoring treatment effectiveness. Various specimens, such as serum or plasma, are used for applications including non-invasive prenatal testing (NIPT), oncology, transcriptomics, pharmacogenomics, transplant rejection, population screening, cardiovascular diseases, and others. These specimens are utilized by a range of end-users, including hospitals, perinatal clinics, public health labs, private or commercial labs, physician labs, research institutes, and others.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The rare biomarkers specimen collection and stabilization market research report is one of a series of new reports from The Business Research Company that provides rare biomarkers specimen collection and stabilization market statistics, including the rare biomarkers specimen collection and stabilization industry global market size, regional shares, competitors with rare biomarkers specimen collection and stabilization market share, detailed rare biomarkers specimen collection and stabilization market segments, market trends, and opportunities, and any further data you may need to thrive in the rare biomarkers specimen collection and stabilization industry. These rare biomarkers specimen collection and stabilization market research reports deliver a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The rare biomarkers specimen collection and stabilization market size has grown rapidly in recent years. It will grow from $32.01 billion in 2024 to $35.29 billion in 2025 at a compound annual growth rate (CAGR) of 10.3%. The growth in the historic period can be attributed to the human genome project, increase in cancer research, pharmaceutical R&D investment, growth of genomics and proteomics, and improved data management and bioinformatics.

The rare biomarkers specimen collection and stabilization market size is expected to see strong growth in the next few years. It will grow to $51.22 billion in 2029 at a compound annual growth rate (CAGR) of 9.8%. The growth in the forecast period can be attributed to the expansion of liquid biopsy applications, consumer awareness and demand, increasing adoption of non-invasive techniques, and biomarker discovery in rare diseases. Major trends in the forecast period include advancements in preservation technology, growth in genomic and proteomic research, the emergence of point-of-care testing, and regulatory advancements and standardization, enhanced data analytics, and AI integration.

The forecast of 9.8% growth over the next five years reflects a modest reduction of 0.6% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. The imposition of tariffs may pose a significant challenge for U.S. labs by restricting access to cryopreservation tubes and stabilizing reagents imported from Denmark and China, potentially compromising rare disease research and increasing biobanking costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The increasing prevalence of cancer is expected to propel the growth of the rare biomarker specimen collection and stabilization market. Cancer, characterized by the uncontrolled proliferation and spread of abnormal cells, is rising in prevalence due to environmental pollutants and lifestyle factors, such as smoking and poor diet choices, which exacerbate genetic predispositions. The utilization of rare biomarker specimen collection and stabilization methods in cancer prevalence studies facilitates more accurate detection and monitoring of specific cancer types, thereby enhancing diagnostic and therapeutic approaches. For example, in October 2023, a report by the European Commission, a Europe-based governing body, indicated that new cancer cases rose to 2.74 million in 2022, reflecting a 2.3% increase from 2020. Consequently, the increasing prevalence of cancer is driving the growth of the rare biomarker specimen collection and stabilization market.

Major companies in the rare biomarker specimen collection and stabilization market are focusing on developing innovative solutions, such as pre-analytical platforms to automate the preparation of plasma and cell samples for multiomic liquid biopsy. Pre-analytical platforms provide consistent, automated fresh sample preparation at the time of blood collection, allowing for complete walk-away processing of whole blood without the need for special tubes or skilled professionals, thus preserving sample integrity. For instance, in May 2022, Tethis S.p.A., an Italy-based biotechnology company, launched See.d, the first fully automated, standardized pre-analytical platform offering unique features such as precise sample handling, efficient separation of plasma for cellular fractions, and fixation of white blood cells on SmartBioSurface slides. The platform includes a quality control scoring system for objectively evaluating sample stability, enabling the systematic scoring of proteomics and metabolomics data sets to determine the stability of plasma and serum samples.

In October 2022, DiaSorin, an Italy-based biotechnology company, acquired Luminex Corporation for an undisclosed amount. With this acquisition, DiaSorin aims to leverage multiplexing technology and Luminex's portfolio to strengthen its existing offerings. This acquisition aims to enhance DiaSorin's diagnostic testing capabilities, expand its market presence, and drive innovation in the molecular and immunodiagnostics sectors. Luminex Corporation is a US-based provider of proprietary biological testing instruments involving rare biomarker specimen collection and stabilization.

Major companies operating in the rare biomarkers specimen collection and stabilization market are F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Abbott Laboratories, Merck KGaA, Becton Dickinson and Company, Eurofins Scientific SE, Agilent Technologies Inc., PerkinElmer Inc., Illumina Inc., Charles River Laboratories International Inc., Bio-Rad Laboratories Inc., Bruker Corporation, QIAGEN N.V., Miltenyi Biotec GmbH, Natera Inc., Promega Corporation, Myriad Genetics, Hamilton Company, OraSure Technologies Inc., Fluidigm Corporation, Streck Inc., SeraCare, Enzo Biochem Inc., Epigenomics AG, Veridex LLC

North America was the largest region in the rare biomarkers specimen collection and stabilization market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the rare biomarkers specimen collection and stabilization market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the rare biomarkers specimen collection and stabilization market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The rare biomarkers specimen collection and stabilization market consists of revenues earned by entities by providing services such as sample collection, stabilization and preservation, customized collection protocols, bio banking and storage and data management and reporting. The market value includes the value of related goods sold by the service provider or included within the service offering. The rare biomarkers specimen collection and stabilization market also includes sales of biomarker collection kits, laboratory equipment, training and educational materials, quality control materials, and sample storage containers. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Rare Biomarkers Specimen Collection And Stabilization Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on rare biomarkers specimen collection and stabilization market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for rare biomarkers specimen collection and stabilization ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The rare biomarkers specimen collection and stabilization market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Rare Biomarkers Specimen Collection And Stabilization Market Characteristics

3. Rare Biomarkers Specimen Collection And Stabilization Market Trends And Strategies

4. Rare Biomarkers Specimen Collection And Stabilization Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Rare Biomarkers Specimen Collection And Stabilization Growth Analysis And Strategic Analysis Framework

6. Rare Biomarkers Specimen Collection And Stabilization Market Segmentation

7. Rare Biomarkers Specimen Collection And Stabilization Market Regional And Country Analysis

8. Asia-Pacific Rare Biomarkers Specimen Collection And Stabilization Market

9. China Rare Biomarkers Specimen Collection And Stabilization Market

10. India Rare Biomarkers Specimen Collection And Stabilization Market

11. Japan Rare Biomarkers Specimen Collection And Stabilization Market

12. Australia Rare Biomarkers Specimen Collection And Stabilization Market

13. Indonesia Rare Biomarkers Specimen Collection And Stabilization Market

14. South Korea Rare Biomarkers Specimen Collection And Stabilization Market

15. Western Europe Rare Biomarkers Specimen Collection And Stabilization Market

16. UK Rare Biomarkers Specimen Collection And Stabilization Market

17. Germany Rare Biomarkers Specimen Collection And Stabilization Market

18. France Rare Biomarkers Specimen Collection And Stabilization Market

19. Italy Rare Biomarkers Specimen Collection And Stabilization Market

20. Spain Rare Biomarkers Specimen Collection And Stabilization Market

21. Eastern Europe Rare Biomarkers Specimen Collection And Stabilization Market

22. Russia Rare Biomarkers Specimen Collection And Stabilization Market

23. North America Rare Biomarkers Specimen Collection And Stabilization Market

24. USA Rare Biomarkers Specimen Collection And Stabilization Market

25. Canada Rare Biomarkers Specimen Collection And Stabilization Market

26. South America Rare Biomarkers Specimen Collection And Stabilization Market

27. Brazil Rare Biomarkers Specimen Collection And Stabilization Market

28. Middle East Rare Biomarkers Specimen Collection And Stabilization Market

29. Africa Rare Biomarkers Specimen Collection And Stabilization Market

30. Rare Biomarkers Specimen Collection And Stabilization Market Competitive Landscape And Company Profiles

31. Rare Biomarkers Specimen Collection And Stabilization Market Other Major And Innovative Companies

32. Global Rare Biomarkers Specimen Collection And Stabilization Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Rare Biomarkers Specimen Collection And Stabilization Market

34. Recent Developments In The Rare Biomarkers Specimen Collection And Stabilization Market

35. Rare Biomarkers Specimen Collection And Stabilization Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기